Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.